Rifampin: profile and news

Trends in Tuberculosis—United States, 2005  16 May 2006
...all non-Hispanic. Persons identified as Hispanic might be of any race. Defined as resistant to at least isoniazid and rifampin. - Journal of American Medical Association (subscription),

New Study Shows Initial Treatment With 800 mg/day Imatinib ...  May 15, 2006
...least 50% and clinical response should be carefully monitored in patients receiving Gleevec tablets with a potent CYP3A4 inducer such as rifampin or phenytoin. ... - DG News

Leaders call for countries to tackle tough TB  May 10, 2006
For more than a decade, health officials have worried about "multidrug-resistant" TB, which can withstand the mainline antibiotics isoniazid and rifampin. ... - Columbus Ledger-Enquirer,

View larger version (35K):  May 3, 2006
The patient was treated with ethambutol, isoniazid, pyrazinamide, and rifampin for six months, with an excellent clinical response. ... - New England Journal of Medicine (subscription),

Inmate dies from infection; rest given antibiotics  May 1, 2006
...passed it on. The state health department was informed and sent 1,440 doses of the antibiotic rifampin to the jail. Inmates and ... - Atlanta Journal Constitution (subscription),

Fatal illness stirs concern at jail  May 2, 2006
...passed it on. The state Health Department was informed and sent 1,440 doses of the antibiotic Rifampin to the jail. Inmates and ... - Atlanta Journal Constitution (subscription),

Drug-resistant strain emerges  Apr 17, 2006
The term refers to bacteria that are resistant to the two first-line therapies normally used to treat the disease, the antibiotics - isoniazid and rifampin. ... - Deccan Herald,

ENZYME INDUCTION: Rifampin is known to induce certain cytochrome P-450 enzymes. Administration of rifampin with drugs that undergo biotransformation through these metabolic pathways may accelerate elimination of coadministered drugs. To maintain optimum therapeutic blood levels, dosages of drugs metabolized by these enzymes may require adjustment when starting or stopping concomitantly administered rifampin.

Rifampin has been reported to accelerate the metabolism of the following drugs: anticonvulsants (eg, phenytoin), antiarrhythmics (eg, disopyramide, mexiletine, quinidine, tocainide), oral anticoagulants, antifungals (eg, fluconazole, itraconazole, ketoconazole), barbiturates, beta-blockers, calcium channel blockers (eg, diltiazem, nifedipine, verapamil), chloramphenicol, clarithromycin, corticosteroids, cyclosporine, cardiac glycoside preparations, clofibrate, oral or other systemic hormone contraceptives, dapsone, diazepam, doxycycline, fluoroquinolones (eg ciprofloxacin), haloperidol, oral hypoglycemic agents (sulfonylureas), levothyroxine, methadone, narcotic analgesics, nortriptyline, progestins, quinine, tacrolimus, theophylline tricyclic antidepressants (eg, amitriptyline, nortriptyline), and zidovudine. It may be necessary to adjust the dosages of these drugs if they are given concurrently with rifampin.

Patients using oral or other systemic hormonal contraceptives should be advised to change to nonhormonal methods of birth control during rifampin therapy.

Rifampin has been observed to increase the requirements for anticoagulant drugs of the coumarin type. In patients receiving anticoagulants and rifampin concurrently, it is recommended that the prothrombin time be performed daily or as frequently as necessary to establish and maintain the required dose of anticoagulant.

Diabetes may become more difficult to control.

OTHER INTERACTIONS: When the two drugs were taken concomitantly, decreased concentrations of atovaquone and increased concentrations of rifampin were observed.

Concurrent use of ketoconazole and rifampin has resulted in decreased serum concentrations of both drugs. Concurrent use of rifampin and enalapril has resulted in decreased concentrations of enalaprilat, the active metabolite of enalapril. Dosage adjustments should be made if indicated by the patient's clinical condition.

Concomitant antacid administration may reduce the absorption of rifampin. Daily doses of rifampin should be given at least 1 hour before the ingestion of antacids.

Probenecid and cotrimoxazole have been reported to increase the blood level of rifampin.

When rifampin is given concomitantly with either halothane or isoniazid, the potential for hepatotoxicity is increased. The concomitant use of rifampin and halothane should be avoided. Patients receiving both rifampin and isoniazid should be monitored close for hepatotoxicity.

Plasma concentrations of sulfapyridine may be reduced following the concomitant administration of sulfasalazine and rifampin. This finding may be the result of alteration in the colonic bacteria responsible for the reduction of sulfasalazine to sulfapyridine and mesalamine.